日本TaKaRa     
TaKaRa Bio Group是世界三大生物工程公司之一，其相关产品在日本市场上的占有率达60%以上，并畅销国际市场。大连TaKaRa公司成立于1993年8月，公司生产和开发生物工程研究用试剂，有DNA限制酶、修饰酶、各种基因操作试剂盒、PCR相关产品等，还开展DNA合成、DNA测序、DNA芯片制作以及其他各种基因工程操作等的全方位服务。此外，TaKaRa还拥有实验条件一流的开放实验室，可以为科研人员的实验顺利进行提供良好条件。现在公司生产的产品除在中国国内进行销售外，有70%出口海外。
宝生物工程(大连)有限公司是由日本TaKaRa Bio株式会社在中国大连经济技术开发区投资兴建的日本独资企业。

Since its beginnings as the biomedical business of Takara Shuzo Co., Ltd. (now Takara HoldingssInc.), Takara Bio has continuously expanded its gene and DNA-related businesses, which havesnow developed into three business segments. In 1979, the Genetic engineering research businessswas launched with the sale of the first domestically produced restriction enzymes. This businessshas now expanded to include a portfolio of genetic engineering research reagents, scientificsinstruments and contract research services that are essential to biotechnology researcherssworldwide. In the AgriBio segment, which was the first to succeed in the large-scale cultivationsof Bunashimeji mushrooms in 1970, we promote a mushroom business that is centered onstechnologies for the large-scale cultivation of mushrooms. We also offer customers such foodsmaterials as kombu (kelp) "fucoidan," agar (vegetable gelatin) "agaoligo," Ashitaba (angelicasherb) "chalcone" and mushroom "terpene," whose functionality has been proven through thesuse of biotechnology. In the Gene medicine segment, we are striving to develop andscommercialize cutting-edge medical technologies, such as gene and cell therapies for cancer andsAIDS, based on technologies developed and accumulated through the activities of our Geneticsengineering research segment.

Our business strategyis to invest the stable income generated by the Genetic engineering research and AgriBio segments into the Gene medicine segment in order to develop gene medicine technologies, thereby expanding our future earnings.

Takara Bio Inc. contributes to the health of mankind by making revolutionary biomedical technology, such as gene therapy, a reality.